Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/42966
Title: | Estimation of antimicrobial resistance of Mycoplasma genitalium, Belgium, 2022 | Authors: | De Baetselier, Irith Smet, Hilde Kehoe, Kaat Loosen, Imelda Reynders , Marijke Mansoor, Iqbal Filippin, Lorenzo Cauchie, Mathieu Van Even, Ellen Makki, Nadia Schiettekatte, Gilberte Vandewal, Wouter Glibert, Bart Matheeussen, Veerle Beken, Yolien Van der Cartuyvels, Reinoud Steyaert, Sophia Lemmens, Ann Garrino, Maria-Grazia Paridaens, Henry Lazarova, Elena Lissoir, Benedicte Deffontaine, Marine Heinrichs, Amelie Saegeman, Veroniek PADALKO, Elizaveta Lecompte, Amaryl Vanden Berghe, Wim Kenyon, Chris Van den Bossche , Dorien |
Issue Date: | 2024 | Publisher: | EUR CENTRE DIS PREVENTION & CONTROL | Source: | Eurosurveillance, 29 (7) (Art N° 2300318) | Abstract: | Background: Antimicrobial resistance (AMR) of Mycoplasma genitalium (MG) is a growing concern worldwide and surveillance is needed. In Belgium, samples are sent to the National Reference Centre of Sexually Transmitted Infections (NRC-STI) on a voluntary basis and representative or robust national AMR data are lacking. Aim: We aimed to estimate the occurrence of resistant MG in Belgium. Methods: Between July and November 2022, frozen remnants of MG -positive samples from 21 Belgian laboratories were analysed at the NRC-STI. Macrolide and fluoroquinolone resistance -associated mutations (RAMs) were assessed using Sanger sequencing of the 23SrRNA and parC gene. Differences in resistance patterns were correlated with surveillance methodology, sociodemographic and behavioural variables via Fisher's exact test and logistic regression analysis. Results: Of the 244 MG -positive samples received, 232 could be sequenced for macrolide and fluoroquinolone RAMs. Over half of the sequenced samples (55.2%) were resistant to macrolides. All sequenced samples from men who have sex with men (MSM) (24/24) were macrolide-resistant. Fluoroquinolone RAMs were found in 25.9% of the samples and occurrence did not differ between socio-demographic and sexual behaviour characteristics. Conclusion: Although limited in sample size, our data suggest no additional benefit of testing MG retrieved from MSM for macrolide resistance in Belgium, when making treatment decisions. The lower occurrence of macrolide resistance in other population groups, combined with emergence of fluoroquinolone RAMs support macrolide-resistance testing in these groups. Continued surveillance of resistance in MG in different population groups will be crucial to confirm our findings and to guide national testing and treatment strategies. | Notes: | De Baetselier, I (corresponding author), Inst Trop Med, Natl Reference Ctr Sexually Transmitted Infect Bel, Dept Clin Sci, Antwerp, Belgium. idebaetselier@itg.be |
Keywords: | Belgium;Europe;Mycoplasma genitalium;antimicrobial resistance;fluoroquinolone resistance;macrolide resistance;Male;Humans;Anti-Bacterial Agents;Homosexuality, Male;Macrolides;Drug Resistance, Bacterial;Mutation;RNA, Ribosomal, 23S;Fluoroquinolones;Mycoplasma Infections;Sexual and Gender Minorities;Sexually Transmitted Diseases | Document URI: | http://hdl.handle.net/1942/42966 | ISSN: | 1025-496X | e-ISSN: | 1560-7917 | DOI: | 10.2807/1560-7917.ES.2024.29.7.2300318 | ISI #: | 001198714100003 | Rights: | This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made. | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
eurosurv-29-7-3.pdf | Published version | 240.22 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.